CXCR1 and melanoma: In fact, the CXCR1/2 axis has been unrevealed as a potential therapeutic target in malignant melanoma, with pathway-inhibition significantly improving sensitivity for chemotherapy in otherwise resistant melanoma cells in vitro [102], while also decreasing progression and metastasis even in advanced disease [103].